Markh Ebell News Today

A study of 718 patients who sought treatment in U.S.-based primary and emergency care settings found that antibiotics were ineffective in providing symptomatic relief.

Monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales, which do not meet the minimal clinically important difference.

Monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales, according to a study,

Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage, and symptomatic ARIA-edema.

Myloid-reducing monoclonal antibodies for patients with Alzheimer have harmful risks, such as cerebral edema, hemorrhage, serious adverse events, and death, according to a new study.